Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 85-88 , 29 December 2009

Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)

  • U. Kassner

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • Corresponding Author InformationCharité University Clinic Campus Virchow, Interdisciplinary Metabolic Care Centre, Augustenburger Platz 1 13353 Berlin Germany
    • ,
  • A. Vogt

      Affiliations

    • Ludwig-Maximilians-Universität München, Germany
    • ,
  • A. Rosada

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • F. Barz

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • E. Giannakidou-Jordan

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • H.K. Berthold

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • E. Steinhagen-Thiessen

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany

Literature 

  1. Berg K . A new serum type system in man: the Lp system . Acta Pathol Microbiol Scand . 1963;59:362–382
  2. Marcovina SM , Koschinsky ML . Lipoprotein(a) as a risk factor for coronary artery disease . Am J Cardiol . 1998;82(12A):57U–66U
  3. Hobbs HH , White AL . Lipoprotein(a): intrigues and insights . Curr Opin Lipidol . 1999;10(3):225–236
  4. Boerwinkle E , Leffert CC , Jingping L , Lackner C , Chiesa G , Hobbs HH . Apolipoprotein(a) accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations . J Clin Invest . 1992;90:52–60
  5. Gaw A , Brown EA , Ford I . Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect . Arterioscler Thromb Vasc Biol . 1998 Dec;18(12):1870–1876
  6. Nielsen LB , Gronholdt MLM , Schroeder TV , Stender S , Nordestgaard BG . In vivo transfer of lipoprotein (a) into human athersclerotic carotid arterial intima . Arterioscler Thromb Vasc Biol . 1997;17(5):905–911
  7. Rath M , Niendorf A , Reblin T , Dietel M , Krebber HJ , Beisiegel U . Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients . Eur Heart J . 1990 Aug;11(Suppl E):174–183
  8. Boffa MB , Marcovina SM , Koschinsky ML . Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models . Clin Biochem . 2004;37(5):333–343.8
  9. Poon M , Zhang X , Dunsky KG , Taubman MB , Harpel PC . Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells . Circulation . 1997;96(8):2514–2519
  10. Cremer P, Nagel D, Labrot B, Mann H, Müller-Berninger R, Elster H, et al. Ten-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men . Atherosclerosis . 1997;129:221–230
  11. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study . JAMA . 1996;276:544–548
  12. Craig WY , Neveux LM , Palomaki GE , Cleveland MM , Haddow JE . Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies . Clin Chem. . 1998 Nov;44(11):2301–2306
  13. Danesh J , Collins R , Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies . Circulation . 2000 Sep 5;102(10):1082–1085
  14. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data . Arch Intern Med . 2008 Mar 24;168(6):598–608
  15. Kamstrup PR , Benn M , Tybjaerg-Hansen A , Nordestgaard BG . Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study . Circulation . 2008 Jan 15;117(2):176–184
  16. Emerging Risk Factors Collaboration , Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality . JAMA . 2009 Jul 22;302(4):412–423
  17. Carlson  , Hamsten  , Asplund  , Carlson LA , Hamsten A , Asplund A , et al.   Pronounced lowering of serum lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic acid . J Intern Med . 1989;226:271
  18. Goldberg A, Alagona P, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia . Am J Cardiol . 2000 May 1;85(9):1100–1105
  19. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice . Circulation . 2008;118:743–753
  20. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events . Nat Clin Pract Cardiovasc Med . 2009 Mar;6(3):229–239
  21. Keller C . Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management . Ther Apher Dial . 2007 Feb;11(1):2–8
  22. Thompson GR , HEART-UK LDL , Apheresis Working Group  . Recommendations for the use of LDL apheresis . Atherosclerosis . 2008 Jun;198(2):247–255
  23. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines . J Am Coll Cardiol . 2004 Aug 4;44(3):720–732 Review.
  24. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary . Atherosclerosis . 2007 Sep;194(1):1–45
  25. G-BA, Blutreinigungsverfahren zur Behandlung einer selten auftretenden Fettstoffwechselstörung wird GKV-Leistung. Homepage G-BA 2008 Jun 20.

PII: S1567-5688(09)71818-5

doi: 10.1016/S1567-5688(09)71818-5

Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 85-88 , 29 December 2009

Article Tools